Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV

Funded by the National Institute on Drug Abuse as a Center of Excellence


Learn about us Publications & Presentations Subscribe
Center for Health Economics of Treatment for Substance Users Is Established at Weill Cornell Medical College Read more

Hepatitis C virus (HCV) is a communicable disease that could lead to liver cirrhosis and hepatocellular carcinoma affecting baby boomers and all people who inject drugs (PWID) in particular. There are over 19,000 HCV-related deaths in the United States annually. HCV can be cured using direct-acting antivirals that can also reverse HCV-related liver injury. In […]

Read the blog post

Using a legislatively-mandated, integrated dataset, the Massachusetts Department of Public Health has published its first comprehensive look at the state’s opioid-related overdoses between 2011 and 2015. The dataset was created as part of 2015 “Chapter 55” legislation. It links information on an individual level across diverse state databases, including mental health data, jail and prison […]

Read the blog post

Tools for researchers to reduce stigma and improve accuracy. News and feature stories about the opioid epidemic appear daily in a variety of media outlets. To draw interest, these outlets often using provocative language to describe substance use disorders and those affected by substance use across the country. The 2017 Associated Press Stylebook, however, now […]

Read the full story

In a groundbreaking announcement, 12 large insurers, covering over 240 million lives, pledged to adopt eight evidence-based “National Principles of Care” for the treatment of substance use disorder (SUD). The initiative is designed to improve care for the 21 million Americans who have an SUD, only 11% of whom receive any treatment at all. The […]

Read the blog post

BLOG

Abuse Deterrent Opioids: A Hard Sell

by Benjamin Ukert, PhD

One strategy to combat the opioid epidemic is to change the formulation of opioids to deter abuse. Reformulations can make opioids harder or less pleasant to inject, snort, or chew, thereby reducing common methods of abuse. Since 2010, the FDA has approved 10 opioid abuse deterrent formulations, which are considerably more expensive than regular brand […]

Read the blog post

Although evidence from health policy research should inform policymaking, researchers and policymakers don’t always communicate. A conference sponsored by the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) – a NIDA-funded Center of Excellence – and hosted by the Leonard Davis Institute of Health Economics (LDI) sought to […]

Read the blog post

A recent statistical brief from the Agency for Healthcare Research and Quality (AHRQ) provides valuable information regarding patient characteristics for opioid-related inpatient stays and emergency department (ED) visits in the US and within 44 states and the District of Columbia. The brief comes from AHRQ’s Healthcare Cost and Utilization Project (HCUP), which is the largest […]

Read the blog post

EVENT


APPAM/ASHecon Webinar: The Intersection of Opioid Addiction and Evidence-Based Policy

Thursday, January 18, 2018
2:00 pm — 3:00 pm
Tony LoSasso, Kosali Simon, Colleen Carey, Jevay Grooms, Carroline Lobo
EVENT


Opioid Disorder Treatments and Comparative Effectiveness: The X:BOT Trial and Current Large RCTs among Community and Correctional Populations

Wednesday, January 24, 2018
12:00 pm — 1:00 pm
Joshua D Lee MD, MSc

Methodology

Experts in cost benefit, cost effectiveness, and budget impact analyses

Learn More Consultation Request

HCV and HIV

Experts in economic analysis of HCV and HIV and treatment among substance users

Learn More Consultation Request

Dissemination and Policy

Experts in disseminating health economic research among policy makers and the public

Learn More Latest Issue Brief

Pilot Grant and Training

Supports new investigators and investigators new to health economic research in substance use disorders, HCV, and HIV

Learn More Pilot Grants